Prosecution Insights
Last updated: October 25, 2026

Ergami Endoscopy

Technology area: Medical Devices & Mechanical Engineering

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Ergami Endoscopy focuses its patent activity in the Medical Devices & Mechanical Engineering technology area. The company has 1 pending office action currently under review. This action is being handled by 1 distinct examiner, FAIRCHILD, AARON BENJAMIN. This 1 focus means that the company's current legal strategy is tied to the review process of 1 specific examiner.

The portfolio's current prosecution is confined to 1 distinct art unit. FAIRCHILD, AARON BENJAMIN serves as the busiest examiner with 1 pending office action. This data shows that the company's immediate legal interactions are concentrated in 1 technical and administrative channel. For a patent practitioner, this suggests a streamlined prosecution process where all current efforts are directed toward 1 art unit. The absence of multiple pending actions or examiners indicates a targeted approach to securing intellectual property in the medical device sector at this stage.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
100% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FAIRCHILD, AARON BENJAMIN 1 79.3% +20.5%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18541689 DEPLOYABLE FLEXIBLE OVERTUBE FAIRCHILD, AARON BENJAMIN —

Top Art Units

Art UnitApps
3795 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18541689 DEPLOYABLE FLEXIBLE OVERTUBE FAIRCHILD, AARON BENJAMIN 3795 §112 Non-Final OA — Pending Dec 15, 2023

Managing Ergami Endoscopy's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ergami Endoscopy have?

Ergami Endoscopy has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Ergami Endoscopy applications?

Aaron Benjamin Fairchild has the most, with 1 of Ergami Endoscopy's pending office actions.

What technology area are Ergami Endoscopy's patent applications in?

Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month